Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Basit Öğe Kaydı
dc.authorid0000-0002-5823-1704
dc.contributor.authorErol, Cihan
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorBayır Garbioğlu, Duygu
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorAkbaş, Sinem
dc.contributor.authorHizal, Mutlu
dc.contributor.authorArslan, Çağatay
dc.contributor.authorSevinç, Alper
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorErdem, Dilek
dc.contributor.authorKahraman, Seda
dc.contributor.authorÇakır, Emre
dc.contributor.authorDemirkıran, Aykut
dc.contributor.authorOn, Sercan
dc.contributor.authorDoğan, İzzet
dc.contributor.authorErdoğan, Atike Pınar
dc.contributor.authorKoca, Sinan
dc.contributor.authorKubilay, Pınar
dc.contributor.authorEren, Orhan Önder
dc.contributor.authorÇılbır, Ebru
dc.contributor.authorÇelik, Emir
dc.contributor.authorAraz, Murat
dc.contributor.authorTataroğlu Özyükseler, Deniz
dc.contributor.authorYıldırım, Mahmut Emre
dc.contributor.authorBahçeci, Aykut
dc.contributor.authorTaşkaynatan, Halil
dc.contributor.authorOyman, Abdilkerim
dc.contributor.authorDeniz, Gülhan İpek
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorGülmez, Ahmet
dc.contributor.authorSakin, Abdullah
dc.contributor.authorNayır, Erdinç
dc.contributor.authorAcar, Ramazan
dc.contributor.authorŞen, Erdem
dc.contributor.authorİnal, Ali
dc.contributor.authorTurhal, Serdar
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorPaydaş, Semra
dc.contributor.authorTaştekin, Didem
dc.contributor.authorHacıbekiroğlu, İlhan
dc.contributor.authorÇinçin, İrfan
dc.contributor.authorBilici, Ahmet
dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorŞener Dede, Didem
dc.contributor.authorAkıncı, Muhammed Bülent
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorUncu, Doğan
dc.contributor.authorYalçın, Bülent
dc.contributor.authorArtaç, Mehmet
dc.date.accessioned2022-12-23T12:06:52Z
dc.date.available2022-12-23T12:06:52Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in patients with metastatic CRC in real-life experience. Materials and Methods: Four hundred and thirty-three patients who treated with FOLFIRI and aflibercept in the second-line were included in the study. The clinical and pathological features of the patients were recorded retrospectively. Survival (overall and progression-free survival [PFS]), response rates, and safety data were analyzed. Results: The median age was 61. Majority of patients (87.5%) received first-line bevacizumab and 10.1% of patients received anti-epidermal growth factor receptor agents. About 80% of patients had KRAS, 18.6% of patients had NRAS, and 6.4% of patients had BRAF mutations. The median OS was 11.6 months (95% confidence interval [CI], 10.6-12.6) and the median PFS was 6 months (95% CI, 5.5-6.5). About 4.6% of patients had complete response and 30.6% of patients had partial response as best tumor response. Grade 1-2 toxicities were seen in 33.4% of patients, while grade 3-4 toxicities were recorded in 27% of patients. Eight patients (2%) died due to treatment toxicity. Conclusions: Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial.
dc.identifier.citationErol, C., Şendur, M. A. N., Bilgetekin, İ., Bayır Garbioğlu, D., Hamdard, J., Akbaş, S. ... Artaç, M. (2022). Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Journal of Cancer Research and Therapeutics, 18, S347-S353. https://doi.org/10.4103/jcrt.jcrt_1104_21
dc.identifier.doi10.4103/jcrt.jcrt_1104_21
dc.identifier.endpageS353
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.pmid36510987
dc.identifier.scopus2-s2.0-85143994465
dc.identifier.scopusqualityQ3
dc.identifier.startpageS347
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1104_21
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10177
dc.identifier.volume18
dc.identifier.wos000908442000034en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHamdard, Jamshid
dc.institutionauthorAkbaş, Sinem
dc.institutionauthorŞen, Erdem
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectAflibercept
dc.subjectClinical Practice
dc.subjectColorectal Cancer
dc.subjectReal Life Data
dc.subjectSecond Line
dc.titleEfficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Hamdard-Jamshid-2022.pdf
Boyut:
782.65 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu